Protocol I: An Open Label Study of Risperidone in Children and Adolescents with Autism and Other Pervasive Disorders. Protocol II: An Open Label Continuation Study of Risperidone in Children and Adolescents with Autism and Other Pervasive Disorders Followed By a Double-Blind, Placebo-Controlled Discontinuation Study.

Trial Profile

Protocol I: An Open Label Study of Risperidone in Children and Adolescents with Autism and Other Pervasive Disorders. Protocol II: An Open Label Continuation Study of Risperidone in Children and Adolescents with Autism and Other Pervasive Disorders Followed By a Double-Blind, Placebo-Controlled Discontinuation Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2012

At a glance

  • Drugs Risperidone (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR294).
    • 07 Jul 2009 Additional lead trial centres, lead investigator (Troost PW) added as reported by ISRCTN: Current Controlled Trials.
    • 08 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top